[1] Zhu L, Jiang J, Zhai X, et al. Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: A population-based cohort study. Liver Int, 2019, 39:70-80. [2] Lee CH, Choi SH, Chung GE, et al. Nonalcoholic fatty liver diseaseis associated with decreased lung function. Liver Int, 2018;38:2091-2100. [3] Mantovani A, Dauriz M, Byrne CD, et al. Association between nonalcoholic fatty liver disease and colorectal Tumours inasymptomatic adults undergoing screening colonoscopy: a systematic reviewand meta-analysis. Metabolism, 2018, 87:1-12. [4] Esposito K, Chiodini P, Capuano A, et al. Metabolic syndrome and postmenopausal breast cancer: systematic reviewand meta-analysis. Menopause, 2013, 20:1301-1309. [5] Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetesand cancer: umbrella review of meta-analyses of observational studies. BMJ, 2015, 350:g7607. [6] Angulo P. Nonalcoholic fatty liver disease. N Engl J Med, 2002; 346:1221-1231. [7] Dibaba DT, Braithwaite D, Akinyemiju T. Metabolic syndrome and the risk of breast cancer and subtypes by race, menopause and BMI. Cancers (Basel), 2018, 10. [8] Nseir W, Abu-Rahmeh Z, Tsipis A, et al. Relationshipbetween non-alcoholic fatty liver disease and breast cancer. Isr Med Assoc J, 2017, 19:242-245. [9] Kim GA, Lee HC, Choe J, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol, 2018, 68:140-146. |